Video

Dr. Shore on next steps with PARP inhibitors in prostate cancer

Author(s):

Urology Times staff

Neal D. Shore, MD, discusses what’s on the horizon with PARP inhibitors in the treatment paradigm for patients with prostate cancer. Shore is medical director for the Carolina Urologic Research Center and chief medical officer, Surgical Oncology and Urology, for Genesis Care (US).

Related Videos
Daniel Kwon, MD, answers a question during a Zoom video interview
DNA helix | Image Credit: © BillionPhotos.com - stock.adobe.com
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
Daniel Kwon, MD, answers a question during a Zoom video interview
Randy A. Vince Jr, MD, MS, answers a question during a Zoom video interview
Related Content
NCCN reaffirms Prolaris’ prognostic value in prostate cancer
December 18th 2024

NCCN reaffirms Prolaris’ prognostic value in prostate cancer

Hannah Clarke
The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.
DNA helix | Image Credit: © Siarhei - stock.adobe.com
December 17th 2024

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer

Patrick Campbell
Test your knowledge of this quiz on the Canadian Urological Association's recommendations for genomic profiling of tumors in prostate cancer.
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
December 10th 2024

Quiz: CUA guidelines on germline genetic testing in prostate cancer

Patrick Campbell
Test your knowledge of this quiz on the Canadian Urological Association's recommendations for germline genetic testing in prostate cancer management.
Epigenomic cfDNA may accurately assess PSMA expression, Lu-PSMA response in mCRPC
November 26th 2024

Epigenomic cfDNA may accurately assess PSMA expression, Lu-PSMA response in mCRPC

Hannah Clarke
“Our study highlights the potential of epigenomic profiling from a simple blood draw to provide a real-time, non-invasive readout of PSMA expression that corresponds with treatment response," says Jacob E. Berchuck, MD.
Survey sheds light on international genetic testing patterns in prostate cancer
November 18th 2024

Survey sheds light on international genetic testing patterns in prostate cancer

Hannah Clarke
Data demonstrated wide variation in the proportion of patients recommended for testing and showed that barriers to testing remain.
Variants of unknown significance may adversely affect RARP outcomes
November 11th 2024

Variants of unknown significance may adversely affect RARP outcomes

Hannah Clarke
In total, 33.3% of patients with a VUS also had positive lymph node involvement and required adjuvant ADT compared with only 16.2% of patients who did not have a VUS.
© 2024 MJH Life Sciences

All rights reserved.